Rossari Biotech Ltd - 543213 - Outcome Of Board Meeting Held On October 30, 2021
The Board has Inter alia approved the following: 1. Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2021. 2. Appointment of Mr. Ketan Sablok as Group Chief Financial Officer. 3. Appointment of Mr. Debashish Vanikar as Chief Executive Officer - New Businesses. 4. Grant of Options under Rossari Employee Stock Option an - 2019. Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Earnings Conference Call for investors and analysts on Monday, November 01, 2021 at 05:30 P.M. IST Rossari Biotech Ltd - 543213 - Board Meeting Intimation for Approval Of Quarterly Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2021
Rossari Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2021 ,inter alia, to consider and approve Unaudited Financial Results (Standalone and Consolidated) for the quarter ended September 30, 2021. Rossari Biotech Ltd - 543213 - Shareholding for the Period Ended September 30, 2021
Rossari Biotech Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2021. For more details, kindly Click here Rossari Biotech Ltd - 543213 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance Certificate under Regulation 74 (5) of SEBI (Depository and Participants) Regulations, 2018 for the quarter ended September 30, 2021 Rossari Biotech Ltd - 543213 - Statement Of Investor Complaints For The Quarter Ended September 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0440 Name of the Signatory :- Parul Gupta Designation :- Company Secretary and Compliance Officer
Rossari Biotech hikes prices, sees 50% jump in revenue, profit this fiscal
The board has set us a target to more than double our revenue and profit from the FY'20 levels by FY'23, both through organic as well as inorganic routes. Rossari Biotech Ltd - 543213 - Closure of Trading Window
Intimation of Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 Rossari Biotech Ltd - 543213 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Rossari Biotech Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here Rossari Biotech Ltd - 543213 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Rossari Biotech Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here